Live News EQUITY FLASH L impact Nov 19, 2026, 12:00 PM UTC Marker Therapeutics receives $16.2 million CPRIT grant for MT-601 trial The grant will support development of MT-601 in the Phase 2 APOLLO study. MRKR SquawkNews Desk